$24.25
Insights on 4d Molecular Therapeutics Inc
Revenue is down for the last 2 quarters, 20.20M → -19.0K (in $), with an average decrease of 100.1% per quarter
Netprofit is down for the last 2 quarters, -10.25M → -32.28M (in $), with an average decrease of 214.8% per quarter
In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 34.3%
In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 269.5%
0.0%
Downside
Day's Volatility :4.45%
Upside
4.45%
61.07%
Downside
52 Weeks Volatility :73.96%
Upside
33.1%
Period | 4d Molecular Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 27.1% | 1.7% | 0.0% |
6 Months | 133.85% | 11.3% | 0.0% |
1 Year | 15.37% | 5.4% | 1.3% |
3 Years | -34.14% | 13.9% | -22.1% |
Market Capitalization | 1.3B |
Book Value | $7.15 |
Earnings Per Share (EPS) | -2.58 |
Wall Street Target Price | 52.2 |
Profit Margin | 0.0% |
Operating Margin TTM | 192905.26% |
Return On Assets TTM | -23.45% |
Return On Equity TTM | -37.41% |
Revenue TTM | 20.7M |
Revenue Per Share TTM | 0.53 |
Quarterly Revenue Growth YOY | 3940.8% |
Gross Profit TTM | -77.1M |
EBITDA | -108.7M |
Diluted Eps TTM | -2.58 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.06 |
EPS Estimate Next Year | -3.4 |
EPS Estimate Current Quarter | -0.74 |
EPS Estimate Next Quarter | -0.76 |
What analysts predicted
Upside of 115.26%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 14.1M | ↑ 144.04% |
Net Income | -9.6M | ↓ 14.9% |
Net Profit Margin | -67.59% | ↑ 126.24% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 7.0M | ↓ 50.56% |
Net Income | -52.9M | ↑ 454.28% |
Net Profit Margin | -757.79% | ↓ 690.2% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 13.6M | ↑ 94.85% |
Net Income | -56.5M | ↑ 6.8% |
Net Profit Margin | -415.38% | ↑ 342.41% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 18.0M | ↑ 32.52% |
Net Income | -68.3M | ↑ 20.79% |
Net Profit Margin | -378.63% | ↑ 36.75% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 3.1M | ↓ 82.65% |
Net Income | -101.1M | ↑ 47.99% |
Net Profit Margin | -3.2K% | ↓ 2851.67% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 20.7M | ↑ 562.29% |
Net Income | -100.8M | ↓ 0.24% |
Net Profit Margin | -486.59% | ↑ 2743.71% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 500.0K | ↑ 208.64% |
Net Income | -24.1M | ↓ 12.09% |
Net Profit Margin | -4.8K% | ↑ 12098.88% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.2M | ↑ 149.4% |
Net Income | -27.3M | ↑ 13.2% |
Net Profit Margin | -2.2K% | ↑ 2631.31% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 298.0K | ↓ 76.1% |
Net Income | -27.3M | ↓ 0.05% |
Net Profit Margin | -9.1K% | ↓ 6959.89% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 239.0K | ↓ 19.8% |
Net Income | -29.6M | ↑ 8.65% |
Net Profit Margin | -12.4K% | ↓ 3244.65% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 20.2M | ↑ 8353.56% |
Net Income | -10.3M | ↓ 65.37% |
Net Profit Margin | -50.76% | ↑ 12340.87% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | -19.0K | ↓ 100.09% |
Net Income | -32.3M | ↑ 214.77% |
Net Profit Margin | 169.9K% | ↑ 169961.29% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 97.0M | ↑ 254.94% |
Total Liabilities | 124.6M | ↑ 165.52% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 58.2M | ↓ 39.95% |
Total Liabilities | 131.2M | ↑ 5.34% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 288.3M | ↑ 395.12% |
Total Liabilities | 31.9M | ↓ 75.65% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 353.5M | ↑ 22.6% |
Total Liabilities | 560.5M | ↑ 1654.58% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 261.8M | ↓ 25.92% |
Total Liabilities | 30.5M | ↓ 94.56% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 339.9M | ↑ 29.81% |
Total Liabilities | 32.1M | ↑ 5.09% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 280.2M | ↓ 7.52% |
Total Liabilities | 28.7M | ↓ 5.59% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 261.8M | ↓ 6.54% |
Total Liabilities | 30.5M | ↑ 6.23% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 244.0M | ↓ 6.81% |
Total Liabilities | 25.4M | ↓ 16.7% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 352.5M | ↑ 44.46% |
Total Liabilities | 725.3M | ↑ 2753.79% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 361.6M | ↑ 2.58% |
Total Liabilities | 31.7M | ↓ 95.63% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 339.9M | ↓ 6.01% |
Total Liabilities | 32.1M | ↑ 1.21% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.3M | ↓ 297.3% |
Investing Cash Flow | -414.0K | ↓ 105.39% |
Financing Cash Flow | 84.6M | ↑ 528506.25% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -36.7M | ↑ 125.89% |
Investing Cash Flow | -3.2M | ↑ 673.67% |
Financing Cash Flow | -2.2M | ↓ 102.6% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -50.9M | ↑ 38.68% |
Investing Cash Flow | -1000.0K | ↓ 68.78% |
Financing Cash Flow | 279.0M | ↓ 12809.93% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -69.1M | ↑ 35.8% |
Investing Cash Flow | -172.7M | ↑ 17168.0% |
Financing Cash Flow | 118.1M | ↓ 57.67% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -86.7M | ↑ 25.39% |
Investing Cash Flow | -17.1M | ↓ 90.13% |
Financing Cash Flow | 3.1M | ↓ 97.39% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -21.0M | ↑ 5.59% |
Investing Cash Flow | 15.4M | ↓ 73.25% |
Financing Cash Flow | 460.0K | ↓ 1020.0% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.2M | ↑ 5.7% |
Investing Cash Flow | -35.8M | ↓ 332.77% |
Financing Cash Flow | 2.0M | ↑ 344.78% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -27.9M | ↑ 25.62% |
Investing Cash Flow | 43.1M | ↓ 220.55% |
Financing Cash Flow | 11.0M | ↑ 437.34% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.1M | ↓ 20.93% |
Investing Cash Flow | 49.3M | ↑ 14.28% |
Financing Cash Flow | 130.5M | ↑ 1087.18% |
Sell
Neutral
Buy
4d Molecular Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
4d Molecular Therapeutics Inc | -27.83% | 133.85% | 15.37% | -34.14% | -40.12% |
Moderna, Inc. | -1.39% | 41.81% | -19.31% | -38.71% | 322.88% |
Regeneron Pharmaceuticals, Inc. | -5.68% | 13.74% | 14.81% | 80.88% | 159.02% |
Novo Nordisk A/s | -2.24% | 29.49% | 49.67% | 240.51% | 421.0% |
Vertex Pharmaceuticals Incorporated | -3.67% | 10.39% | 20.74% | 84.71% | 129.52% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
4d Molecular Therapeutics Inc | NA | NA | NA | -3.06 | -0.37 | -0.23 | NA | 7.15 |
Moderna, Inc. | 24.73 | NA | 0.0 | -6.77 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.13 | 26.13 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 48.36 | 48.36 | 2.4 | 3.34 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 29.17 | 29.17 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
4d Molecular Therapeutics Inc | Buy | $1.3B | -40.12% | NA | 0.0% |
Moderna, Inc. | Buy | $41.3B | 322.88% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.6B | 159.02% | 26.13 | 30.14% |
Novo Nordisk A/s | Buy | $573.9B | 421.0% | 48.36 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $104.7B | 129.52% | 29.17 | 36.68% |
Viking Global Investors LP
RA Capital Management, LLC
Bvf Inc
BlackRock Inc
HHG PLC
VR Adviser, LLC
4d Molecular Therapeutics Inc’s price-to-earnings ratio stands at None
Read Morethe mission of 4d molecular therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. a large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4d products. 4d has one of the deepest and most diverse product pipelines in the gene therapy field. adeno-associated virus (aav) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. they can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. several aav gene therapy products are in late-stage clinical development, and one product is approved in the eu (glybera, uniqure). however, these first-generation aav vectors have lim
Organization | 4d Molecular Therapeutics Inc |
Employees | 147 |
CEO | Dr. John F. Milligan Ph.D. |
Industry | Healthcare |
Acorda Therapeutics, Inc.
$24.25
-2.26%
Sight Sciences Inc
$24.25
-2.26%
Sangamo Therapeutics, Inc.
$24.25
-2.26%
Corbus Pharmaceuticals Holdings, Inc.
$24.25
-2.26%
Redhill Biopharma Ltd-sp Adr
$24.25
-2.26%
Fusion Pharmaceuticals Inc
$24.25
-2.26%
Geron Corporation
$24.25
-2.26%
Iradimed Corp
$24.25
-2.26%
Dbv Technologies S.a.
$24.25
-2.26%